MERCK & CO INC (MRK)
Balfour Capital Group Researched Merck and Co Inc on December 9th, 2022.
Merck & Co Inc (MRK) is a prominent pharmaceutical company, globally recognized for its innovative research and development of drugs and vaccines that contribute to medical advancements and public health.
Post Recommendation Price Trend Chart The chart's commencement marks the instance of our stock recommendation.
- We have established a Buy recommendation at $108.75 on December 9th, 2022.
- Our designated price target stands at $145.00.
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
THOMSON REUTERS ON MRK
THOMSON REUTERS
VIEW MORE
ARGUS ANALYST ON MRK
ARGUS ANALYST NOTES
VIEW MORE ARGUS QUANTITIVE ON MRK
ARGUS QUANTITIVE REPORT
VIEW MORE
Balfour Capital Group wants to clarify that our recommendation to Buy MERCK & CO INC (MRK) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*